Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Is pre-treatment liver biopsy necessary for all hepatitis C genotypes?

Annals of hepatology - 1 Jan 2000

Peltekian Kevork M, Bain Vincent G, Lee Samuel S, Sherman Morris, Cooper Curtis L, Yoshida Eric M, Marotta Paul J, Krajden Mel, Balshaw Robert, Deschênes Marc

Abstract excerpt

BACKGROUND: Current practice guidelines recommend liver biopsy prior to treatment of hepatitis C genotype-1 but not for genotype-2/3; this is based on expert opinion, not on published evidence. METHODS: In retrospective analysis of a large trial database prior to the publication of recent guidelines, we compared outcomes in 985 treatment-naïve patients with hepatitis C who did or did not undergo liver biopsy...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Biopsy

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Hepatitis C

Share to Interferon-alpha

Share to Interferon alpha-2

Share to Polyethylene Glycols

Share to Practice Guidelines as Topic

Share to Ribavirin

Source

Identifiers

PMID: 21677327

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Is pre-treatment liver biopsy necessary for all hepatitis C genotypes?PMID 21677327Read ↗

Cost effectiveness of fibrosis assessment prior to treatment for chronic hepatitis C patients.Semantic proximity Read ↗

Histological findings, genotype distribution and percentage of patients fulfilling the treatment criteria among patients with chronic hepatitis C virus infection in a single Swedish centre.Semantic proximity Read ↗

Positive predictive value of sustained virologic response 4 weeks posttreatment for achieving sustained virologic response 12 weeks posttreatment in patients receiving glecaprevir/pibrentasvir in Phase 2 and 3 clinical trials.Semantic proximity Read ↗

Pretreatment evaluation of chronic hepatitis C: risks, benefits, and costs.Semantic proximity Read ↗

Effect of significant histologic steatosis or steatohepatitis on response to antiviral therapy in patients with chronic hepatitis C.Semantic proximity Read ↗

Incidentally detected asymptomatic hepatitis C virus infection with significant fibrosis: Possible impacts on management.Semantic proximity Read ↗

Mini-laparoscopy outperforms transjugular liver biopsy in patients with acute-on-chronic liver failure: a case-control studySemantic proximity Read ↗

Extended duration therapy with pegylated interferon and ribavirin for patients with genotype 3 hepatitis C and advanced fibrosis: final results from the STEPS trial.Semantic proximity Read ↗

Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients.Semantic proximity Read ↗

Do steatosis and steatohepatitis impact on sustained virological response (SVR) rates in patients receiving pegylated interferon and ribavirin for chronic hepatitis C infection?Semantic proximity Read ↗

Most patients with HCV-associated lymphoma present with mild liver disease: a call to revise antiviral treatment prioritization.Semantic proximity Read ↗

Effect of steatosis and inflammation on liver fibrosis in chronic hepatitis C.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.